Ovarian role in the modulation of pituitary responsiveness to growth hormone-releasing hormone in rats.

Aguilar E, Pinilla L

Neuroendocrinology1 Sept 1991Cited by 7 (Europe PMC)

PMID1834957DOI10.1159/000125889PepBankPUB-01834957

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In intact and ovariectomized female rats, GHRH 1-29 NH2 stimulated GH secretion on days 45, 60 and 90 but not on day 30.
In plain wordsIn female rats, GHRH raised growth hormone at 45, 60 and 90 days of age but not at 30 days.
Peptide
Sermorelin
Outcome
MixedGH secretion after GHRH by age
Study
ratn: not reported in source
female Wistar rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
5 micrograms/kg · intravenousAs given in this study (rat).
Source sentences
Summary
(b) GHRH stimulated GH secretion in intact and ovariectomized females on days 45, 60 and 90, but not on day 30
1 context sentence(design, population, supporting numbers)
Summary · context
The influence of ovarian function on the pituitary responsiveness to growth hormone-releasing hormone (GHRH) was studied by measuring GH levels in serum before and after the injection of GHRH 1-29 NH2 (5 micrograms/kg i.v.) in female Wistar rats under sodium pentobarbital anesthesia (50 mg/kg i.p.).
Report a problemFND-0183495701

Studies that did not test the peptide alone3

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

02AnimalNot a test of Sermorelin aloneAnimal study (in vivo)Mechanism
In female rats, pituitary responsiveness to GHRH changed throughout the estrous cycle, being maximal in diestrus and minimal in proestrus.
In plain wordsIn female rats, the growth hormone response to GHRH changed across the cycle, highest in diestrus and lowest in proestrus.
Peptide
Sermorelin
Outcome
MixedPituitary GH responsiveness to GHRH across estrous cycle
Study
ratn: not reported in source
female Wistar rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
(a) pituitary responsiveness to GHRH changes throughout the estrous cycle is maximal in diestrus and minimal in proestrus
1 context sentence(design, population, supporting numbers)
Summary · context
The influence of ovarian function on the pituitary responsiveness to growth hormone-releasing hormone (GHRH) was studied by measuring GH levels in serum before and after the injection of GHRH 1-29 NH2 (5 micrograms/kg i.v.) in female Wistar rats under sodium pentobarbital anesthesia (50 mg/kg i.p.).
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-0183495702
03AnimalNot a test of Sermorelin aloneAnimal study (in vivo)Mechanism
In female rats, the age-related increase of GH responsiveness to GHRH was slightly reduced in animals ovariectomized on day 23.
In plain wordsIn female rats, removing the ovaries on day 23 slightly reduced the usual age-related rise in the growth hormone response to GHRH.
Peptide
Sermorelin
Outcome
DecreaseGH responsiveness to GHRH after ovariectomy on day 23
Study
ratn: not reported in source
female Wistar rats
Comparator
Sham-operated
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
(c) the age increase of GH responsiveness to GHRH administration was slightly reduced in animals ovariectomized on day 23
1 context sentence(design, population, supporting numbers)
Summary · context
The influence of ovarian function on the pituitary responsiveness to growth hormone-releasing hormone (GHRH) was studied by measuring GH levels in serum before and after the injection of GHRH 1-29 NH2 (5 micrograms/kg i.v.) in female Wistar rats under sodium pentobarbital anesthesia (50 mg/kg i.p.).
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-0183495703
04AnimalNot a test of Sermorelin aloneAnimal study (in vivo)Mechanism
In female rats, ovariectomy on day 83 reduced pituitary responsiveness to GHRH more effectively than ovariectomy on day 23.
In plain wordsIn female rats, removing the ovaries on day 83 reduced the growth hormone response to GHRH more than removing them on day 23.
Peptide
Sermorelin
Outcome
DecreaseGH responsiveness to GHRH after ovariectomy on day 83
Study
ratn: not reported in source
female Wistar rats
Comparator
Ovariectomy on day 23
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
(d) ovariectomy on day 83 reduced pituitary responsiveness to GHRH more effectively than ovariectomy on day 23
1 context sentence(design, population, supporting numbers)
Summary · context
The influence of ovarian function on the pituitary responsiveness to growth hormone-releasing hormone (GHRH) was studied by measuring GH levels in serum before and after the injection of GHRH 1-29 NH2 (5 micrograms/kg i.v.) in female Wistar rats under sodium pentobarbital anesthesia (50 mg/kg i.p.).
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-0183495704

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.